Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: I-124 PET/CT imaging Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT05635045
View directory record Official record
Conditions
Transthyretin Amyloidosis
Interventions
I 124-Evuzamitide
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 105 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 17, 2026, 11:39 PM EDT
Completed No phase listed Observational

PET/CT Imaging of Malignant Brain Tumors With 124I-NM404

NCT01516905
View directory record Official record
Conditions
Glioblastoma, Brain Metastases
Interventions
NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 17, 2026, 11:39 PM EDT
Completed Not applicable Interventional Results available

PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

NCT01540513
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Metastases
Interventions
NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 1, 2019 · Synced Sep 17, 2026, 11:39 PM EDT
Terminated Early Phase 1 Interventional

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

NCT01632696
View directory record Official record
Conditions
Malignant Solid Tumor
Interventions
I-124 PGN650 for PET/CT
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 17, 2026, 11:39 PM EDT
Terminated Phase 2 Interventional Results available

Brivanib Metastatic Renal Cell Carcinoma

NCT01253668
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 17, 2026, 11:39 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

NCT02152995
View directory record Official record
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
Interventions
Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib
Procedure · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Recruiting Phase 2 Interventional

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

NCT05758493
View directory record Official record
Conditions
Amyloidosis, Transthyretin Amyloidosis
Interventions
124I-Evuzamitide
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Recruiting Phase 1 Interventional

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358
View directory record Official record
Conditions
Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Interventions
PET/CT Scan, Iodine-124
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

PET/CT Imaging in Carriers of TTR Mutations

NCT07591038
View directory record Official record
Conditions
ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
Interventions
Iodine-124 Evuzamitide (I-124E)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Enrolling by invitation Phase 2 Interventional

124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

NCT06907849
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
Interventions
124I-evuzamitide
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Completed Phase 3 Interventional

REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

NCT06788535
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
I-124 evuzamitide
Drug
Lead sponsor
Sharmila Dorbala
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

NCT05968846
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Completed Phase 1 Interventional

NM404 as an Imaging Agent in Patients With NSCLC

NCT00582283
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
I124-NM404
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 17, 2026, 11:39 PM EDT
Recruiting No phase listed Observational

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

NCT06443866
View directory record Official record
Conditions
Thyroid Cancer, RAI-Refractory Thyroid Cancer
Interventions
Disease status detection, Theranostic dosimetry, I-124 PET/CT imaging
Diagnostic Test · Drug
Lead sponsor
Miami Cancer Research Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 17, 2026, 11:39 PM EDT
Recruiting Phase 2 Interventional

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

NCT06961084
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Iodine-124, Positron Emission Tomography (PET)/Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
13 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 17, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Results available

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

NCT00199888
View directory record Official record
Conditions
Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney, Renal Neoplasms, Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma
Interventions
124-Iodine-cG250 (124I-cG250)
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 17, 2026, 11:39 PM EDT